Research and Technology Development Sample Clauses

Research and Technology Development. (1) The Parties acknowledge that innovative technological solutions are integral to the success of the FSP and to enable Australia’s sovereign operational and sustainment capability for the Future Submarine. (2) To this end, the Parties shall coordinate and collaborate where appropriate on research and development activities, particularly on most recent developments and technical breakthroughs in the naval domain. (3) Such research and development activities shall be conducted under the instruments referred to in paragraph 4 of this Article. (4) The Parties shall revise, when necessary, the existing Agreement between the Government of Australia and the Government of the Republic of France Concerning Collaboration on Defence Research and Technology, which entered into force 17 December 1990, and may revise existing, or conclude new, subsidiary administrative arrangements for the purposes of the FSP.
View SourceView Similar (2)
Research and Technology Development. The so-called Clinical Trials Directive of 2001 (Directive 2001/20/EC) provides regulative and administrative provisions relating to implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. The term “good clinical practice” refers to a set of internationally recognised ethical and scientific quality requirements which must be observed for designing, conducting, recording and reporting clinical trials that involve the participation of human subjects in the European Union’s Member States (Art. 1.2). A subsequent Directive (Directive 2005/28/EC) lays down principles and more detailed guidelines for good clinical practice. Here, a number of basic principles are set out to be followed by every trial that falls within the scope of the Clinical Trial Directive (Art. 2), as follows:  The rights, safety and wellbeing of trial subjects shall prevail over the interests of science and society.  Each individual involved in conducting a trial shall be qualified by education, training, and experience to perform his tasks.  Clinical trials shall be scientifically sound and guided by ethical principles in all their aspects.  The necessary procedures to secure the quality of every aspect of the trials shall be complied with.
View Source
Research and Technology Development. The so-called Clinical Trials Directive of 2001 (Directive 2001/20/EC) provides regulatory and administrative provisions relating to implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. The term “good clinical practice” refers to a set of internationally recognised ethical and scientific quality requirements which must be observed for designing, conducting, recording and reporting
View Source

Related to Research and Technology Development

  • Technology Research Analyst Job# 1810 General Characteristics

  • New Technology When new or updated technology is introduced into a workplace, it will be the responsibility of the employer to provide appropriate and, if necessary, ongoing training to the employees directly affected. Such training will include any health and safety implications or information that will enable employees to operate the equipment without discomfort and will help maintain their general well-being.

  • Technology Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.

  • Manufacturing Technology Transfer Except as provided in Section 4.3(f)(iii)(1) and Section 6.10, with respect to any Collaboration Product (or LGC Reserved Product, if applicable) for which LGC (or its Affiliate) performed CMC Development or CMC Manufacturing, if (a) Cue does not elect for LGC to perform CMC Step 2, CMC Step 3, or CMC Step 4 (or with respect to LGC Reserved Products, upon completion of CMC Step 1), or (b) upon failure of the Parties to reach agreement with respect to a Clinical Supply Agreement or a Commercial Supply Agreement or (c) [***] under this Agreement and does not cure such breach within [***] days (provided, that if such breach is not reasonably capable of cure within such [***] day period, then such cure period shall be automatically extended for an additional [***] day period as long as LGC continues to use diligent efforts to cure such breach in accordance with a reasonable cure plan and if such breach is not reasonably capable of cure within such combined [***] day period, then Cue shall reasonably consider consenting to any extension of such cure period as long as LGC continues to use diligent efforts to cure such breach in accordance with a reasonable cure plan), as applicable, then, in each case upon the written request of Cue, LGC shall use Commercially Reasonable Efforts to make a technology transfer to an Approved CMO the Manufacturing processes (including materials and such other information) but solely as is necessary to enable the Manufacture of such Collaboration Product (including the Collaboration Compound therein) (or LGC Reserved Product, including the LGC Reserved Compound therein, if applicable) by such Approved CMO to comparable biochemical structure, quality and purity as that Manufactured by LGC or its Affiliate or CMO, provided that neither Cue, LGC or any Third Party shall perform such a technology transfer to any CMO [***] without LGC’s consent, not to be unreasonably withheld, conditioned or delayed if LGC has approved the CMO to manufacture Collaboration Products (or LGC Reserved Products, if applicable). LGC shall conduct such technology transfer as soon as reasonably practicable after receiving such written notice, using good faith efforts to support supply needed to achieve timelines in the Cue Territory Development Plan (or Cue’s development plan for LGC Reserved Products, if applicable) or Cue Territory Commercialization Plan, as applicable. LGC shall conduct the first technology transfer for each Collaboration Product (or LGC Reserved Products, if applicable) [***] (provided that [***]) for a period of up to [***] months from the date Cue or its designee has provided notice it is ready to receive the technology transfer, provided, that such [***] month period [***]. After the expiration of the initial such [***] month period for a Collaboration Product (or LGC Reserved Products, if applicable), if required to complete the technology transfer to enable the Manufacture of such Collaboration Product (including the Collaboration Compound therein) (or LGC Reserved Product, including the LGC Reserved Compound therein, if applicable) by such Approved CMO to comparable biochemical structure, quality and purity as that Manufactured by LGC, LGC shall continue to provide support to Cue for up to an additional [***] period for up to [***] hours at the FTE Rate and thereafter at [***]. Thereafter, LGC will also provide [***] for such Collaboration Product (or LGC Reserved Products, if applicable). Neither Cue nor its Affiliates or Cue Collaborators shall reverse engineer any materials provided hereunder by LGC. Notwithstanding anything in this Agreement to the contrary, LGC’s CMC information may only be shared with an Approved CMO.

  • Research and Development (i) Advice and assistance in relation to research and development of Party B; (ii) Advice and assistance in strategic planning; and